You are here

AstraZeneca

Novo Nordisk picks AstraZeneca executive to head biopharma business

Yahoo/Reuters

Mon, 10/15/18 - 10:38 am

Ludovic Helfgott

3 Big Pharma Stocks Racing Along the Road to China

Motley Fool

Fri, 10/12/18 - 10:20 am

Entasis dips in first trading day after $75M IPO

BioCentury

Wed, 09/26/18 - 07:26 pm

With CDC backing reinstated, AstraZeneca ships FluMist for the coming flu season

Fierce Pharma

Wed, 09/26/18 - 09:50 am

FluMist Quadrivalent

Data Confirms AstraZeneca's Imfinzi Provides Unprecedented Improvement in Progression-Free Survival in Non-Small Cell Lung Cancer

CP Wire

Tue, 09/25/18 - 11:50 am

non-small cell lung cancer

Data Confirms AstraZeneca's Imfinzi Provides Unprecedented Improvement in Progression-Free Survival in Non-Small Cell Lung Cancer

Tue, 09/25/18 - 09:51 am

non-small cell lung cancer

AstraZeneca CEO Pascal Soriot: ‘I’m the lowest-paid CEO in the whole industry’

Endpoints

Mon, 09/24/18 - 11:12 pm

Farxiga Meets One Primary Endpoint in Large Ph III Cardiovascular Outcomes Trial in 17,000 Patients with Type 2 Diabetes

CP Wire

Mon, 09/24/18 - 10:01 am

clinical trials

type 2 diabetes

cardiovascular disease

PhaseBio details dollars in AstraZeneca deal as it rolls out a plan for $86M-plus IPO

Endpoints

Mon, 09/24/18 - 09:44 am

anti-anti-coagulants

Farxiga Meets One Primary Endpoint in Large Ph III Cardiovascular Outcomes Trial in 17,000 Patients with Type 2 Diabetes

Mon, 09/24/18 - 09:36 am

AstraZeneca CEO warns of medicine shortages after Brexit: Sunday Times

Yahoo/Reuters

Sun, 09/23/18 - 01:47 pm

AZ expands role in China, to include robots and health tech

Pharmaforum

Thu, 09/20/18 - 10:03 am

artificial intelligence

AstraZeneca, shut out of COPD, touts long-term Fasenra asthma data

Fierce Pharma

Tue, 09/18/18 - 10:13 pm

With latest data, can AstraZeneca's COPD triple combo rival Glaxo's Trelegy?

Fierce Pharma

Mon, 09/17/18 - 12:13 pm

Trelegy Ellipta

AstraZeneca grabs an FDA OK for its new leukemia drug, to be marketed as Lumoxiti

Endpoints

Thu, 09/13/18 - 11:22 pm

hairy cell leukemia

moxetumomab pasudotox

AstraZeneca plc (AZN) Expected to Post Earnings of $0.44 Per Share

Daily Political

Mon, 09/10/18 - 12:22 am

Another setback for AstraZeneca as lupus drug fails phase 3 test

Fierce Biotech

Fri, 08/31/18 - 11:43 am

systemic lupus erythematosus

clinical trials

AstraZeneca improves diabetes pen to maintain its market share

Pharmaforum

Fri, 08/31/18 - 10:52 am

Jumping ahead of AstraZeneca, AbbVie and J&J get a green light to market Imbruvica/Rituxan combo for rare lymphoma

Endpoints

Mon, 08/27/18 - 10:02 am

non-Hodgkin's lymphoma

Waldenström’s macroglobulinemia

Major Expected Events from AstraZeneca’s R&D in H2 2018

Market Realist

Sat, 08/25/18 - 09:24 pm

Pages